Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 4, 2011, Pages 428-435

  Witte, Anne Barbara ^a   Grybäck, Per ^a   Jacobsson, Hans ^a   Näslund, Erik ^b   Hellström, Per Martin ^c   Holst, Jens Juul ^d   Hilsted, Linda ^d   Schmidt, Peter Thelin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Exendin 9 39; gastric emptying; GLP 1; glucagon; insulin

Indexed keywords

EXENDIN 4; EXENDIN(9-39)AMIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PEPTIDE YY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NORMAL HUMAN; PANCREAS SECRETION; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH CONTENT; STOMACH EMPTYING; STOMACH MOTILITY;

ADULT; BLOOD GLUCOSE; FEMALE; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; HUNGER; INSULIN; MALE; NAUSEA; PANCREAS; PEPTIDE FRAGMENTS; PEPTIDE YY; POSTPRANDIAL PERIOD; SATIATION;

EID: 79952611982     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.537680     Document Type: Article

References (35)

1. Göke R, Fehmann HC, Göke B. Glucagon-like peptide-1 (7-36) amide is a new incretin/enterogastrone candidate. Eur J Clin Invest 1991;21:135-44.
2. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992;22:283-91.
3. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, ørskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 1997; 273:E981-8.
4. Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, et al. Effects of intravenous glucagon-like peptide- 1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006; 91:1916-23.
5. Kielgast, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 2009;5:266-75.
6. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73.
7. Schirra J, Katschinski M, Weidmann C, Schäfer T, Wank U, Arnold R, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996:97:92-103.
8. Willms B, Werner J, ørskov C, Holst JJ, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-32.
9. Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Göke B, et al. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 1997;109:84-97.
10. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol 2002;282: G424-31.
11. Näslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999;277:R910-6.
12. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide-1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-25.
13. Wettergren A, Maina P, Boesby S, Holst JJ. Glucagon-like peptide-1 7-36 amide and PYY have additive inhibitory effect on gastric acid secretion in man. Scand J Gastroenterol 1997; 32:552-5.
14. Camilleri M. Integrated upper gastrointestinal response to food intake. Gastroenterology 2006;131:640-58.
15. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007;56:1475-80.
16. Woerle H, Lindenberger T, Linke R, Foley J, Ligueros- Saylan M, Zhang Y, et al. A single dose of vildagliptin (VILDA) decelerates gastric emptying (GE) in patients with type 2 diabetes (T2DM). Diabetes 2007;56:A133 (Abstract).
17. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 2009;23:479-86.
18. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Ex(9-39)amide is an antagonist of glucagon- like peptide-1(7-36)amide in humans. J Clin Invest 1998;101:1421-30.
19. Salehi M, Vahl TP, D'Allessio DA. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 2008;93:4909-16.
20. Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010; 95:215-21.
21. Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Göke B. GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 2009;21:609-18.
22. Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-9.
23. Grybäck P, Hermansson G, Lyrenäs E, Beckman KW, Jacobsson H, Hellström PM. Nationwide standardization and evaluation of scintigraphic gastric emptying: reference values and comparisons between subgroups in a multicentre trial. Eur J Nucl Med 2000;27:647-55.
24. Holst JJ. Evidence that enteroglucan (II) is identical with the C-terminal sequence (residues 33-39) of glicentin. Biochem J 1982;207:381-8.
25. Schmidt PT, Ljung T, Hartmann B, Hare KJ, Holst JJ, Hellström PM. Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. Eur J Gastroenterol Hepatol 2005;17:207-12.
26. Schirra J, Houk P, Wank U, Arnold R, Göke B,Katschinski M. Effects of glucagon-like peptide-1(7-36) amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000; 46:622-31.
27. Schirra J, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 2002;50: 341-8.
28. Villsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with Type 1 and Type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706-13.
29. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol 2000;278:E1010-8.
30. Gutniak MK, ørskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-37) in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316-22.
31. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans. Diabetes 1999;48:86-93.
32. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloroduodenal motility in humans. Gut 2006;55:243-51.
33. Salehi M, Aulinger B, Prigeon RL, D'Alessio DA. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes 2010;59:1330-7.
34. Jonderko G, Golab T, Jonderko K. A pharmacological dose of glucagon suppresses gastric emptying of a radiolabelled solid meal in humans. Scand J Clin Lab Invest 1988;48: 743-6.
35. Kong MF, King P, MacDonald IA, Blackshaw PE, Perkins AC, Armstrong E, et al. Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects. Diabetologia 1998; 41:474-81.